JP6947649B2 - 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン - Google Patents
複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン Download PDFInfo
- Publication number
- JP6947649B2 JP6947649B2 JP2017565248A JP2017565248A JP6947649B2 JP 6947649 B2 JP6947649 B2 JP 6947649B2 JP 2017565248 A JP2017565248 A JP 2017565248A JP 2017565248 A JP2017565248 A JP 2017565248A JP 6947649 B2 JP6947649 B2 JP 6947649B2
- Authority
- JP
- Japan
- Prior art keywords
- salmonella
- pharmaceutical composition
- protein
- seq
- cancer
- Prior art date
- Legal status (The legal status is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the status listed.)
- Active
Links
Images
Classifications
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K35/00—Medicinal preparations containing materials or reaction products thereof with undetermined constitution
- A61K35/66—Microorganisms or materials therefrom
- A61K35/74—Bacteria
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/39—Medicinal preparations containing antigens or antibodies characterised by the immunostimulating additives, e.g. chemical adjuvants
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001102—Receptors, cell surface antigens or cell surface determinants
- A61K39/001103—Receptors for growth factors
- A61K39/001109—Vascular endothelial growth factor receptors [VEGFR]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001152—Transcription factors, e.g. SOX or c-MYC
- A61K39/001153—Wilms tumor 1 [WT1]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/001166—Adhesion molecules, e.g. NRCAM, EpCAM or cadherins
- A61K39/001168—Mesothelin [MSLN]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/0005—Vertebrate antigens
- A61K39/0011—Cancer antigens
- A61K39/00118—Cancer antigens from embryonic or fetal origin
- A61K39/001182—Carcinoembryonic antigen [CEA]
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/02—Bacterial antigens
- A61K39/025—Enterobacteriales, e.g. Enterobacter
- A61K39/0275—Salmonella
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K39/395—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum
- A61K39/39533—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals
- A61K39/39558—Antibodies; Immunoglobulins; Immune serum, e.g. antilymphocytic serum against materials from animals against tumor tissues, cells, antigens
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K45/00—Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
- A61K45/06—Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P35/00—Antineoplastic agents
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
- A61P37/00—Drugs for immunological or allergic disorders
- A61P37/02—Immunomodulators
- A61P37/06—Immunosuppressants, e.g. drugs for graft rejection
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/505—Medicinal preparations containing antigens or antibodies comprising antibodies
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/522—Bacterial cells; Fungal cells; Protozoal cells avirulent or attenuated
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/52—Bacterial cells; Fungal cells; Protozoal cells
- A61K2039/523—Bacterial cells; Fungal cells; Protozoal cells expressing foreign proteins
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/51—Medicinal preparations containing antigens or antibodies comprising whole cells, viruses or DNA/RNA
- A61K2039/53—DNA (RNA) vaccination
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K39/00—Medicinal preparations containing antigens or antibodies
- A61K2039/58—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation
- A61K2039/585—Medicinal preparations containing antigens or antibodies raising an immune response against a target which is not the antigen used for immunisation wherein the target is cancer
-
- A—HUMAN NECESSITIES
- A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
- A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
- A61K2300/00—Mixtures or combinations of active ingredients, wherein at least one active ingredient is fully defined in groups A61K31/00 - A61K41/00
-
- Y—GENERAL TAGGING OF NEW TECHNOLOGICAL DEVELOPMENTS; GENERAL TAGGING OF CROSS-SECTIONAL TECHNOLOGIES SPANNING OVER SEVERAL SECTIONS OF THE IPC; TECHNICAL SUBJECTS COVERED BY FORMER USPC CROSS-REFERENCE ART COLLECTIONS [XRACs] AND DIGESTS
- Y02—TECHNOLOGIES OR APPLICATIONS FOR MITIGATION OR ADAPTATION AGAINST CLIMATE CHANGE
- Y02A—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE
- Y02A50/00—TECHNOLOGIES FOR ADAPTATION TO CLIMATE CHANGE in human health protection, e.g. against extreme weather
- Y02A50/30—Against vector-borne diseases, e.g. mosquito-borne, fly-borne, tick-borne or waterborne diseases whose impact is exacerbated by climate change
Landscapes
- Health & Medical Sciences (AREA)
- Life Sciences & Earth Sciences (AREA)
- Chemical & Material Sciences (AREA)
- Medicinal Chemistry (AREA)
- Pharmacology & Pharmacy (AREA)
- Veterinary Medicine (AREA)
- Public Health (AREA)
- General Health & Medical Sciences (AREA)
- Animal Behavior & Ethology (AREA)
- Immunology (AREA)
- Epidemiology (AREA)
- Microbiology (AREA)
- Mycology (AREA)
- Oncology (AREA)
- Engineering & Computer Science (AREA)
- Chemical Kinetics & Catalysis (AREA)
- General Chemical & Material Sciences (AREA)
- Bioinformatics & Cheminformatics (AREA)
- Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
- Organic Chemistry (AREA)
- Cell Biology (AREA)
- Vascular Medicine (AREA)
- Reproductive Health (AREA)
- Developmental Biology & Embryology (AREA)
- Gynecology & Obstetrics (AREA)
- Pregnancy & Childbirth (AREA)
- Biomedical Technology (AREA)
- Transplantation (AREA)
- Molecular Biology (AREA)
- Medicines Containing Antibodies Or Antigens For Use As Internal Diagnostic Agents (AREA)
- Medicines Containing Material From Animals Or Micro-Organisms (AREA)
- Micro-Organisms Or Cultivation Processes Thereof (AREA)
- Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
- Medicinal Preparation (AREA)
- Peptides Or Proteins (AREA)
Applications Claiming Priority (3)
| Application Number | Priority Date | Filing Date | Title |
|---|---|---|---|
| EP15001803.4 | 2015-06-18 | ||
| EP15001803 | 2015-06-18 | ||
| PCT/EP2016/001004 WO2016202459A1 (en) | 2015-06-18 | 2016-06-16 | Vegfr-2 targeting dna vaccine for combination therapy |
Publications (3)
| Publication Number | Publication Date |
|---|---|
| JP2018517419A JP2018517419A (ja) | 2018-07-05 |
| JP2018517419A5 JP2018517419A5 (cg-RX-API-DMAC7.html) | 2019-05-30 |
| JP6947649B2 true JP6947649B2 (ja) | 2021-10-13 |
Family
ID=53476620
Family Applications (1)
| Application Number | Title | Priority Date | Filing Date |
|---|---|---|---|
| JP2017565248A Active JP6947649B2 (ja) | 2015-06-18 | 2016-06-16 | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン |
Country Status (19)
Families Citing this family (6)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| RU2019112977A (ru) * | 2016-11-04 | 2020-12-04 | Факсимм Аг | Днк-вакцина, нацеленная на wt1, для комбинированной терапии |
| SG11201907391SA (en) * | 2017-02-17 | 2019-09-27 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| US11357842B2 (en) | 2017-03-17 | 2022-06-14 | Vaximm Ag | PD-L1 targeting DNA vaccine for cancer immunotherapy |
| CA3109430A1 (en) * | 2018-09-05 | 2020-03-12 | Vaximm Ag | Neoantigen targeting dna vaccine for combination therapy |
| AU2021208400A1 (en) * | 2020-01-13 | 2022-08-11 | Vaximm Ag | Salmonella-based DNA vaccines in combination with an antibiotic |
| EP3922255A1 (en) * | 2020-06-10 | 2021-12-15 | Prokarium Limited | Cancer therapy |
Family Cites Families (10)
| Publication number | Priority date | Publication date | Assignee | Title |
|---|---|---|---|---|
| US7094410B2 (en) | 2002-03-02 | 2006-08-22 | The Scripps Research Institute | DNA vaccine against proliferating endothelial cells and methods of use thereof |
| NO337687B1 (no) | 2011-07-08 | 2016-06-06 | Norsk Elektro Optikk As | Hyperspektralt kamera og metode for å ta opp hyperspektrale data |
| BR112014015706A2 (pt) * | 2011-12-22 | 2020-10-27 | Vaximm Ag | método para o cultivo de uma estirpe mutante atenuada de salmonella typhi, estirpe mutante atenuada de salmonella typhi e salmonella typhi ty21a |
| BR112014033046A2 (pt) * | 2012-07-05 | 2017-06-27 | Vaximm Ag | linhagem mutante atenuada de salmonella typhi, vacina de dna e vacina de dna vxm01 |
| PT2897620T (pt) * | 2012-09-21 | 2020-09-03 | Intensity Therapeutics Inc | Método de tratamento de cancro |
| SG10201710472PA (en) * | 2013-02-22 | 2018-02-27 | Curevac Ag | Combination of vaccination and inhibition of the pd-1 pathway |
| CN105246496A (zh) * | 2013-04-25 | 2016-01-13 | 万科斯蒙股份有限公司 | 用于癌症免疫治疗的靶向肾母细胞瘤基因wt-1的基于沙门菌的载体 |
| BR112016014405A2 (pt) * | 2013-12-18 | 2018-02-20 | Vaximm Gmbh | cepa mutante atenuada de salmonela |
| SG11201907391SA (en) * | 2017-02-17 | 2019-09-27 | Vaximm Ag | Novel vegfr-2 targeting immunotherapy approach |
| US11357842B2 (en) * | 2017-03-17 | 2022-06-14 | Vaximm Ag | PD-L1 targeting DNA vaccine for cancer immunotherapy |
-
2016
- 2016-06-16 JP JP2017565248A patent/JP6947649B2/ja active Active
- 2016-06-16 SI SI201630549T patent/SI3310379T1/sl unknown
- 2016-06-16 RU RU2018101722A patent/RU2018101722A/ru not_active Application Discontinuation
- 2016-06-16 KR KR1020257001040A patent/KR20250024816A/ko active Pending
- 2016-06-16 CN CN201680035593.2A patent/CN107995868B/zh active Active
- 2016-06-16 US US15/737,659 patent/US10905752B2/en active Active
- 2016-06-16 PL PL16736381T patent/PL3310379T3/pl unknown
- 2016-06-16 DK DK16736381.1T patent/DK3310379T3/da active
- 2016-06-16 KR KR1020187001398A patent/KR20180037948A/ko not_active Ceased
- 2016-06-16 LT LTEP16736381.1T patent/LT3310379T/lt unknown
- 2016-06-16 WO PCT/EP2016/001004 patent/WO2016202459A1/en not_active Ceased
- 2016-06-16 ES ES16736381T patent/ES2760699T3/es active Active
- 2016-06-16 EP EP16736381.1A patent/EP3310379B1/en active Active
- 2016-06-16 ES ES19205420T patent/ES2994561T3/es active Active
- 2016-06-16 HU HUE16736381A patent/HUE046631T2/hu unknown
- 2016-06-16 CA CA2989247A patent/CA2989247C/en active Active
- 2016-06-16 BR BR112017027378-0A patent/BR112017027378A2/pt not_active Application Discontinuation
- 2016-06-16 MX MX2017016183A patent/MX2017016183A/es unknown
- 2016-06-16 PL PL19205420.3T patent/PL3626262T3/pl unknown
- 2016-06-16 EP EP19205420.3A patent/EP3626262B1/en active Active
- 2016-06-16 AU AU2016278588A patent/AU2016278588B2/en active Active
-
2017
- 2017-12-04 IL IL256076A patent/IL256076A/en unknown
- 2017-12-12 ZA ZA2017/08439A patent/ZA201708439B/en unknown
-
2020
- 2020-11-30 US US17/107,203 patent/US20210077605A1/en active Pending
Also Published As
Similar Documents
| Publication | Publication Date | Title |
|---|---|---|
| US10293037B2 (en) | DNA vaccine for use in pancreatic cancer patients | |
| JP6947649B2 (ja) | 複合治療のためのｖｅｇｆｒ−２標的化ｄｎａワクチン | |
| JP7247097B2 (ja) | がん免疫療法のための新規ｐｄ－ｌ１標的ｄｎａワクチン | |
| JP2023160838A (ja) | 新規ｖｅｇｆｒ－２ターゲット免疫療法アプローチ | |
| JP2019533698A (ja) | 併用療法のためのｗｔ１標的指向性ｄｎａワクチン | |
| HK40026195A (en) | Vegfr-2 targeting dna vaccine for combination therapy | |
| HK40026195B (en) | Vegfr-2 targeting dna vaccine for combination therapy | |
| HK1252435B (en) | Vegfr-2 targeting dna vaccine for combination therapy | |
| CA2877938C (en) | Dna vaccine for use in pancreatic cancer patients | |
| JP2023510770A (ja) | 抗生剤と組み合わせた、サルモネラベースのｄｎａワクチン |
Legal Events
| Date | Code | Title | Description |
|---|---|---|---|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20190418 |
|
| A621 | Written request for application examination |
Free format text: JAPANESE INTERMEDIATE CODE: A621 Effective date: 20190418 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20200303 |
|
| A977 | Report on retrieval |
Free format text: JAPANESE INTERMEDIATE CODE: A971007 Effective date: 20200228 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20200603 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20201110 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210209 |
|
| A131 | Notification of reasons for refusal |
Free format text: JAPANESE INTERMEDIATE CODE: A131 Effective date: 20210511 |
|
| A521 | Request for written amendment filed |
Free format text: JAPANESE INTERMEDIATE CODE: A523 Effective date: 20210727 |
|
| TRDD | Decision of grant or rejection written | ||
| A01 | Written decision to grant a patent or to grant a registration (utility model) |
Free format text: JAPANESE INTERMEDIATE CODE: A01 Effective date: 20210817 |
|
| A61 | First payment of annual fees (during grant procedure) |
Free format text: JAPANESE INTERMEDIATE CODE: A61 Effective date: 20210916 |
|
| R150 | Certificate of patent or registration of utility model |
Ref document number: 6947649 Country of ref document: JP Free format text: JAPANESE INTERMEDIATE CODE: R150 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |
|
| R250 | Receipt of annual fees |
Free format text: JAPANESE INTERMEDIATE CODE: R250 |